

ADVIK LABORATORIES LIMITED

Regd. Off. :138, Roz Ka Meo Industrial Area, Sohna, Distt. Mewat Haryana - 122103

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2017

CIN : L74899HR1994PLC038300

Sr No	Particulars	(Rs in Lacs except EPS)			
		Quarter ended			Year Ended
		30-Jun-17 (Unaudited)	31-Mar-17 (Audited)	30-Jun-16 (Unaudited)	31-Mar-17 (Audited)
1	Income from Operation				
	(a) Net Sales/Revenue from Operations	126.54	33.42	29.69	226.86
	(b) Other Operating Income	9.56	19.49	18.93	57.46
	(c) Other Income	0.01	0.01	0.80	2.44
	Total Income	136.11	52.92	49.42	286.76
2	Expenses				
	a) Cost of Materials consumed	59.05	304.61	30.16	461.70
	b) Purchase of Stock-in-trade	-	-	-	-
	c) Changes in Inventory of Finished goods, Work-in-progress and Stock-in-trade	51.23	(25.14)	378.17	362.06
	d) Employee Benefits Expenses	17.50	22.04	18.47	77.75
	e) Finance Costs	0.02	-	0.03	0.09
	f) Depreciation and Amortisation expense	14.70	14.75	14.72	59.03
	g) Other expenses	17.40	19.87	14.03	69.12
	Total Expenses	159.90	336.13	455.58	1,029.75
3	Profit/(Loss) before Exceptional items and tax (1-2)	(23.79)	(283.21)	(406.16)	(742.99)
4	Exceptional Items	-	-	-	-
5	Profit/(Loss) before tax (3 + 4)	(23.79)	(283.21)	(406.16)	(742.99)
6	Tax Expense				
	- Current tax	-	-	-	-
	- Deferred tax	(1.16)	-	-	(5.65)
	Total Tax Expenses	(1.16)	-	-	(5.65)
7	Profit/(Loss) for the period (5-6)	(22.63)	(283.21)	(406.16)	(737.34)
8	Other Comprehensive Income (net of tax)	0.39	-	0.36	-
9	Total Other Comprehensive Income for the period	0.39	-	0.36	-
10	Total Comprehensive Income for the period (7+9)	(22.24)	(283.21)	(405.80)	(737.34)
11	Paid-up equity share capital (face value of Rs 10/- per share)	1,911.14	1,911.14	1,911.14	1,911.14
12	Earning per share (EPS) of Rs 10/- each (not annualized)				
	(1) Basic	(0.12)	(1.48)	(2.12)	(3.86)
	(2) Diluted	(0.12)	(1.48)	(2.12)	(3.86)

- Notes:
- The results for the Quarter ended June 30, 2017 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 14th September 2017. The above results for the quarter ended June 30, 2017 have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The IND AS compliant financial results pertaining to quarter ended June 30, 2016 has not been subjected to the Limited Review. However, the Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
 - This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the company has for the first time adopted Ind AS with a transition date of April 1, 2016. Though maximum information have been extracted from the books of accounts maintained by the Company, yet the implementation of IND AS is still under progress.
 - As the Company's business activity falls within a single Primary segment viz. : "Pharmaceutical", the disclosure requirement of Accounting Standard (AS-17) "Segment Reporting" is not applicable.
 - The statement does not include Ind AS compliant results for the preceding quarter and previous year ended March 31, 2017, as it is not mandatory as per SEBI's circular dated July 5, 2016.
 - The format for un-audited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's circular dated July 5, 2016, IND AS and Schedule III (Division It) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS.



6)	The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with IND AS is given below:	
	Description	Quarter ended June 30, 2016 (unaudited)
	Net Profit as per previous GAAP (Indian GAAP)	(406.16)
	Add/Less: Increase/(Decrease) in Net Profit as reported under Indian GAAP	
	Actuarial Loss/(Gain) on Defined Benefit Plan Recognised in OCI	(0.36)
	Net Profit as per IND AS	(406.52)
	Other Comprehensive Income, net of income tax	0.36
	Total Comprehensive Income for the period	(406.16)
7)	Previous period figures are re-arranged/re-grouped wherever necessary.	



For and on behalf of Board of Directors of
Advik Laboratories Ltd.

(Signature)
(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423

Place: New Delhi
Date : 14.09.2017



RMA & ASSOCIATES LLP
Chartered Accountants
LLPIN: AAI-9419 / (ISO 9001:2015)

Address: Plot No. - 75, LGF,
Patparganj Industrial Area, Delhi - 110092
Phone: 011 - 45261214
E-Mail: rma.ca12@gmail.com
Website: www.rma-ca.com

Limited Review Report to

The Board of Directors
Advik Laboratories Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s. Advik Laboratories Limited** for the quarter ended 30th June, 2017 attached herewith, being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/ FAC/62/ 2016 dated July 5, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

Attention is drawn to the fact that the figures for the corresponding quarter ended 30 June, 2016 including the reconciliation of profit under Indian Accounting Standards (Ind AS) of the corresponding quarter with profit reported under previous GAAP, as reported in these unaudited Financial results have been approved by company's Board of Directors but have not been subjected to review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagements to Review of Interim Financial Information performed by Independent Auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s. RMA & Associates LLP
Chartered Accountants
FRN: 000978N/N500062

Rajiv Bajpai

Rajiv Bajpai
(Partner)
(Membership No. 405219)

Place: New Delhi
Date: 14th September, 2017

